NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission this week, Thermo Fisher Scientific reported that its Life Sciences Solutions segment recorded $80 million of net restructuring and other charges, including $6.2 million of third-party transaction and integration costs related to the acquisitions of Life Technologies and Advanced Scientifics, and $23.7 million for severance. The company also reported its Analytical Instruments segment recorded $26.4 million of net restructuring and other charges, $22.1 million of which were cash costs primarily associated with abandoned facilities. The Specialty Diagnostics segment recorded $10.1 million of net restructuring and other charges, including $9.7 million of net restructuring and other costs, primarily cash costs for employee severance and other costs associated with headcount reductions. And the Laboratory Products and Services segment recorded $24.9 million of net restructuring and other charges, including $7.7 million of cash restructuring costs primarily for employee severance and other costs associated with headcount reductions. The company’s corporate segment recorded $29.3 million of restructuring and other costs, including $2 million of cash restructuring costs primarily for severance at its corporate operations.
CareDx announced this week that it has revised the timeline for its acquisition offer to the shareholders of Allenex AB. The company said it needs to update its prospectus to reflect recent changes in the working capital financing available to it after the offer closes, and that this information will also need additional review by CareDx's Swedish and US auditors. The firm now expects approval and publication of the prospectus by Mar. 7, and hopes to complete the offer in April.
In a filing with the US Securities and Exchange Commission this week, Fluidigm reported that it entered into a patent purchase agreement with PerkinElmer on Nov. 4 to buy certain of its mass cytometry patents for $6.5 million. The companies also signed a patent assignment agreement under which PerkinElmer transferred and assigned all rights, title, privileges, and interest in and to the patents to Fluidigm. The firms had previously had a long-standing agreement for Fluidigm to license the technology in question from PerkinElmer. Pursuant to the purchase of the patents, Fluidigm has now granted PerkinElmer a license to some of the technology.
Pressure BioSciences announced this week that it has closed the first tranche of the over-subscription amount of its $5 million private placement, after receiving $550,000 in gross proceeds from the sixth overall closing of the offering. The total amount raised in the offering is now $5.56 million. The initial terms of the offering limited the amount the company could raise to $6.25 million ($5 million plus a $1.25 million over-subscription amount). The company then approved an increase in the over-subscription amount to $2.5 million, which increased the capacity of the offering to a maximum of $7.5 million. Following this recent closing, $1.94 million remains available in the offering.
Biocept announced this week that it has signed an agreement with preferred provider organization network Prime Health Services to grant it network access to Biocept's liquid biopsy testing.
Trovagene said this week that it signed an agreement with Multiplan to give health plan members who use the PHCS, Multiplan, and Beech Street networks access to Trovagene's full line of Precision Cancer Monitoring tests and services.
Interpace Diagnostics announced this week that it has signed an agreement with America's Choice Provider Network to provide coverage for all of Interpace's molecular tests, including PancraGEN for the diagnosis of pancreatic cancer from cysts, and the ThyGenX/ThyraMIR combination test to improve pre-operative diagnosis and surgical management of patients with indeterminate thyroid nodules.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.